Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

Slides:

Advertisements

Similar presentations

The Nurse’s Role in Inflammatory Bowel Disease

Advertisements

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Nurse View.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

NOACs for Cancer-Associated Thrombosis:

TITLE Authors Institution RESULTS INTRODUCTION CONCLUSION AIMS METHODS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Advanced NSCLC Without Actionable Mutations

Introduction. Looking Beyond HIV Infection: CCR5 Blockade as an Immunomodulatory Concept

Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Endocrine System.

Introduction to Checkpoint Inhibitors

The Tumor Microenvironment

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

Activity Goals. Activity Goals Discussion Topics.

Chronic Idiopathic Urticaria

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Optimizing Management of Advanced Bladder Cancer

Checkpoint Inhibition

Managing gBRCA-Positive Metastatic Breast Cancer

The Nurse View: Top Ten Things to Know About Immune-Mediated Adverse Events.

Checkpoint Inhibition

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Gene Therapy: Past, Present, and Future

Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Skin.

Managing Adverse Events With New Oral Therapies in CLL

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Optimizing Outcomes and Managing Adverse Events in CLL

Immunotherapy for cSCC

Battling Constipation

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Hiding in Plain Sight: How Cancer Evades the Immune System

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Multidisciplinary Approaches to Managing Hemophilia

Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Management of Advanced Pancreatic Adenocarcinoma

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Optimizing Joint Health in Hemophilia

Possible Causes of imAEs

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

Communicating With Your Patients About Major Depressive Disorder

Challenges in LA SCCHN.

From Adjuvant to Metastatic in Melanoma

Strengthening Lung Cancer Team Connections to Improve Outcomes With Immunotherapy.

When Good Isn't Good Enough

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Oral Therapies in MS.

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

Checkpoint Inhibitors in First-Line Advanced NSCLC

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

The Nurse View: Spotlight on EGFR-Mutated NSCLC

A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Pulmonary Arterial Hypertension and Hospitalizations

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Immune Checkpoint Inhibitors in Lung Cancer

The Nurse View.

Care Team Collaboration for CAR T-Cell Therapy: Real-World Advice

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Overview of irAEs. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy.

Interprofessional Approach to Managing Adverse Events of PI3K Inhibitors.

Presentation transcript:

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract

Introduction

Possible Mechanisms

Organ Systems Affected by Immune Checkpoint Blockade

General Principles of Management

The Team Approach

Educating the Front Lines

Specialists

GU-Mediated AEs

Role of Kidney Function

Cisplatin-Ineligible Patients With Bladder Cancer

PD-1/PD-L1 Blockade in Cisplatin-Ineligible Patients With Bladder Cancer

Case 1

Approaches Prior to Instituting Systemic Therapy

Case 1 (cont)

Monitoring

Imaging

Case 1 (cont)

Concerns

Case 1 Conclusion

Case 2

Concerns

Case 2 (cont)

Multidisciplinary Care

Nephritis

Management of Nephritis

Case 2 Conclusion

Concluding Remarks

Abbreviations